(9CI)-N-甲基-1H-嘌呤-8-胺 | 23658-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: (9CI)-N-甲基-1H-嘌呤-8-胺
• 英文名称: n-Methyl-7h-purin-8-amine
• CAS: 23658-67-5
• 化学式: C₆H₇N₅
• mdl: MFCD20617039
• 分子量: 149.15
• InChiKey: DNBMRENNZIQFFS-UHFFFAOYSA-N

物化性质

• 熔点：
  332-334 °C (decomp)
• 沸点：
  283.6±23.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

文献信息

• COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF
  申请人：WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD.

  公开号：US20200190066A1

  公开（公告）日：2020-06-18

  It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators.

  该内容涉及作为自噬调节剂的化合物及其制备和使用方法，具体提供了一类具有通用公式(I)的化合物，或其药用可接受盐，这是一种自噬调节剂，特别是哺乳动物ATG8同源物调节剂。
• Novel phosphonate derivatives of certain nucleosides
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0477454A1

  公开（公告）日：1992-04-01

  This invention relates to novel phosphonate derivatives of certain nucleoside analogs, to the methods for their preparation and to their use as anti-viral agents.

  这项发明涉及某些核苷类似物的新磷酸酯衍生物，涉及它们的制备方法以及它们作为抗病毒药物的用途。
• Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
  申请人：Hummersone Marc Geoffrey

  公开号：US20080194546A1

  公开（公告）日：2008-08-14

  There is provided a compound of formula I: wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; R 7 is selected from halo, OR O1 , SR S1 , NR N1 R N2 , NR N7a C(═O)R C1 , NR N7b SO 2 R S2a , an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 5-20 aryl group, where R O1 and R S1 are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N1 and R N2 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N1 and R N2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R C1 is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 1-7 alkyl group or NR N8 R N9 , where R N8 and R N9 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N8 and R N9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R S2a is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N7a and R N7b are selected from H and a C 1-4 alkyl group; R N3 and R N4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR O2 , SR S2b , NR N5 R N6 , an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, wherein R O2 and R S2b are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N5 and R N6 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, or R N5 and R N6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R 2 is unsubstituted morpholino. R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N, and when R 2 is unsubstituted piperidinyl, R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X is not N. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一种化合物，其化学式为I：其中：X5、X6和X8中的一个或两个是N，其余为CH；R7选自卤素、ORO1、SRS1、NRN1RN2、NRN7aC（═O）RC1、NRN7bSO2RS2a、可选取代的C5-20杂环芳基基团或可选取代的C5-20芳基基团，其中RO1和RS1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN1和RN2独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN1和RN2与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RC1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团、可选取代的C1-7烷基基团或NRN8RN9，其中RN8和RN9独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN8和RN9与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RS2a选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN7a和RN7b选自H和C1-4烷基基团；RN3和RN4与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；R2选自H、卤素、ORO2、SRS2b、NRN5RN6、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，其中RO2和RS2b选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN5和RN6独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，或RN5和RN6与它们所连接的氮原子一起形成含有3至8个环原子的杂环环，或其药学上可接受的盐，但当R2为未取代的吗啡啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的吗啡啶基，R7为未取代的苯基，且X5为CH时，X6不是N且X8不是CH，或X6不是CH且X8不是N，当R2为未取代的哌啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的哌啶基，R7为未取代的苯基，且X5为CH时，X6不是CH且X不是N。还提供了制造化合物I的方法，以及将化合物I用作药物治疗癌症的用途。
• NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
  申请人：RIKAGAKU KENKYUSHO

  公开号：EP0311694A1

  公开（公告）日：1989-04-19

  The present invention relates to dideoxynucleoside derivatives useful as antiviral agents, intermediates useful for synthesizing them and synthetic processes thereof. The processes of the present invention are characterized in that a mesyl group, a tosyl group or a trifluoromethanesulfonyl group is selectively introduced into the ribose 3'-position of the various nucleoside derivatives in which the base component, the ribose 2'-position, and 5'- position are protected and then treated with a base and a reducing agent to produce effectively intermediates useful for synthesizing dideoxynucleoside derivatives. By employing this process, various novel intermediadtes and dideoxynucleoside derivatives can be obtained. Further, the present invention provides the process for synthesizing the intermediates useful for synthesizing dideoxynucleoside derivatives, which comprises reacting an alkaline compound with nucleoside derivatives in which the base component, the ribose 2'-position and the ribose 5'-position are protected with pivaloyl groups and the ribose 3'-position is protected with a mesyl group, a tosyl group or a trifluoromethanesulfonyl group to selectively eliminate only the pivaloyl group of the base to thereby produce the intermediate.

  本发明涉及用作抗病毒剂的二脱氧核苷衍生物、用于合成它们的中间体及其合成工艺。 本发明工艺的特点是，在碱基成分、核糖 2'- 位和 5'- 位受到保护的各种核苷衍生物的核糖 3'- 位上，选择性地引入一个甲磺酰基、一个甲苯磺酰基或一个三氟甲磺酰基，然后用碱和还原剂处理，从而有效地生成用于合成双脱氧核苷衍生物的中间体。采用这种工艺可以获得各种新型中间体和二脱氧核苷衍生物。 此外，本发明还提供了用于合成二脱氧核苷衍生物的中间体的合成工艺，该工艺包括将碱性化合物与核苷衍生物反应，其中碱基成分、核糖 2'- 位和核糖 5'- 位被新戊酰基保护，核糖 3'- 位被甲磺酰基、甲苯磺酰基或三氟甲磺酰基保护，以选择性地只消除碱基的新戊酰基，从而生成中间体。
• Novel fluorophosphonate nucleotide derivatives
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0335770A2

  公开（公告）日：1989-10-04

  This invention relates to fluoromethylphosphonate derivatives of certain nucleosides, to methods for their preparation and to their use as antiviral and antitumoral agents.

  本发明涉及某些核苷的氟甲基膦酸盐衍生物、其制备方法及其作为抗病毒剂和抗肿瘤剂的用途。